Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH....

Full description

Bibliographic Details
Main Authors: Jain, Mukul R., Giri, Suresh R., Bhoi, Bibhuti, Trivedi, Chitrang, Rath, Akshyaya, Rathod, Rohan, Ranvir, Ramchandra, Kadam, Shekhar, Patel, Hiren, Swain, Prabodha, Roy, Sib Sankar, Das, Nabanita, Karmakar, Eshani, Wahli, Walter, Patel, Pankaj R.
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Journal Article
Language:English
Published: 2019
Subjects:
NAFLD
Science::Medicine
Dual‐PPAR Agonist
Online Access:https://hdl.handle.net/10356/106322
http://hdl.handle.net/10220/49606

Internet

https://hdl.handle.net/10356/106322
http://hdl.handle.net/10220/49606

Similar Items